48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
January 2026 in “Vestnik dermatologii i venerologii” In this review, the authors report that tacrolimus ointment shows promise for expanding its use to a variety of skin conditions, beyond its current approval for atopic dermatitis, by analyzing clinical experiences of its application for rosacea, seborrheic dermatitis, psoriasis, and other dermatoses.
February 2025 in “Indian Dermatology Online Journal” The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.
July 2025 in “Pakistan Journal of Intensive Care Medicine” In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.
June 2022 in “Pakistan Journal of Medical and Health Sciences” This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.